• Popular
    • Medicine
    • Radiology
    • Cardiology
    • Surgery
    • Nanomedicine
    • Military Medicine
    • Rehab
  • Categories
    • Exclusive
    • A-D
      • Anesthesiology
      • Art
      • Cardiac Surgery
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diagnostics
    • E-I
      • Emergency Medicine
      • ENT
      • Genetics
      • Geriatrics
      • GI
      • Informatics
    • M-N
      • Medicine
      • Military Medicine
      • Nanomedicine
      • Net News
      • Neurology
      • Neurosurgery
      • Nuclear Medicine
    • O-P
      • Ob/Gyn
      • Oncology
      • Ophthalmology
      • Orthopedic Surgery
      • Pathology
      • Pediatrics
      • Plastic Surgery
      • Psychiatry
      • Public Health
    • R-V
      • Radiation Oncology
      • Radiology
      • Rehab
      • Reproductive Medicine
      • Space Medicine
      • Sports Medicine
      • Surgery
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
  • SUBSCRIBE
  • Submit PR
  • About
  • Follow
    • Facebook
    • Twitter
    • Linkedin
    • Youtube
    • Instagram
    • RSS
  • Submit PR
  • Log in
Medgadget
Medgadget
  • Popular
    • Medicine
      Flexible Sensors Detect Heavy Metals in Sweat

      Flexible Sensors Detect Heavy Metals in Sweat

      Nanopore Sensor to Study Protein Aggregation in Neurodegeneration

      Nanopore Sensor to Study Protein Aggregation in Neurodegeneration

      Biobots Use Optogenetic Muscle Actuators for Movement

      Biobots Use Optogenetic Muscle Actuators for Movement

      Exciting Medtech at the Healthcareᐩ Expo Taiwan

      Exciting Medtech at the Healthcareᐩ Expo Taiwan

    • Radiology
      Ultrasound Tornado Rapidly Disrupts Blood Clots

      Ultrasound Tornado Rapidly Disrupts Blood Clots

      Exciting Medtech at the Healthcareᐩ Expo Taiwan

      Exciting Medtech at the Healthcareᐩ Expo Taiwan

      Fluorescence Imaging System Illuminates Tumor Depth

      Fluorescence Imaging System Illuminates Tumor Depth

      Soft Robot Grows Like a Plant to Travel Through Tight Spaces

      Soft Robot Grows Like a Plant to Travel Through Tight Spaces

    • Cardiology
      Belt Monitors Heart Failure Patients

      Belt Monitors Heart Failure Patients

      Camera Measures Blood Pressure with Quick Look

      Camera Measures Blood Pressure with Quick Look

      Monitoring Congestive Heart Failure Through Speech: Interview with Tamir Tal, CEO of Cordio Medical

      Monitoring Congestive Heart Failure Through Speech: Interview with Tamir Tal, CEO of Cordio Medical

      Device Measures Hemoglobin More Accurately in Dark Skin

      Device Measures Hemoglobin More Accurately in Dark Skin

    • Surgery
      Microneedle Bandage for Hemostatic Control

      Microneedle Bandage for Hemostatic Control

      Biobots Use Optogenetic Muscle Actuators for Movement

      Biobots Use Optogenetic Muscle Actuators for Movement

      Implantable Device Adheres to Muscle, Treats Atrophy

      Implantable Device Adheres to Muscle, Treats Atrophy

      Device Measures Hemoglobin More Accurately in Dark Skin

      Device Measures Hemoglobin More Accurately in Dark Skin

    • Nanomedicine
      Extra Hot Nanoparticles for Cancer Therapy

      Extra Hot Nanoparticles for Cancer Therapy

      Making Tumors Tastier for the Immune System

      Making Tumors Tastier for the Immune System

      Improved Membrane Coating for Anti-Cancer Nanoparticles

      Improved Membrane Coating for Anti-Cancer Nanoparticles

      Magnetic Bacteria Target Tumors

      Magnetic Bacteria Target Tumors

    • Military Medicine
      Device Measures Hemoglobin More Accurately in Dark Skin

      Device Measures Hemoglobin More Accurately in Dark Skin

      Fingertip Sensor Measures Lithium Levels in Sweat

      Fingertip Sensor Measures Lithium Levels in Sweat

      Fabric Makes Electricity from Movement to Power Wearables

      Fabric Makes Electricity from Movement to Power Wearables

      Wearable Uses Microneedles to Track Metabolism

      Wearable Uses Microneedles to Track Metabolism

    • Rehab
      Smart Walking Stick for Visually Impaired People

      Smart Walking Stick for Visually Impaired People

      Implantable Device Adheres to Muscle, Treats Atrophy

      Implantable Device Adheres to Muscle, Treats Atrophy

      Non-Invasive Spinal Modulation for Cerebral Palsy

      Non-Invasive Spinal Modulation for Cerebral Palsy

      Implanted Magnets for Prosthetic Control

      Implanted Magnets for Prosthetic Control

  • Categories
    • Exclusive
    • A-D
      • Anesthesiology
      • Art
      • Cardiac Surgery
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diagnostics
    • E-I
      • Emergency Medicine
      • ENT
      • Genetics
      • Geriatrics
      • GI
      • Informatics
    • M-N
      • Medicine
      • Military Medicine
      • Nanomedicine
      • Net News
      • Neurology
      • Neurosurgery
      • Nuclear Medicine
    • O-P
      • Ob/Gyn
      • Oncology
      • Ophthalmology
      • Orthopedic Surgery
      • Pathology
      • Pediatrics
      • Plastic Surgery
      • Psychiatry
      • Public Health
    • R-V
      • Radiation Oncology
      • Radiology
      • Rehab
      • Reproductive Medicine
      • Space Medicine
      • Sports Medicine
      • Surgery
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
  • SUBSCRIBE
  • Submit PR
  • About
  • Log in
  • Submit PR
  • Follow
    • Facebook
    • Twitter
    • Linkedin
    • Youtube
    • Instagram
    • RSS

Conversation on CureVac’s RNA-Based Therapeutics with CEO Ingmar Hoerr

May 28th, 2014 Tom Fowler Diagnostics, Exclusive, News

CureVacIn the late 1990s, Dr. Ingmar Hoerr, founder and CEO of CureVac GmbH, made an unusual discovery in his doctoral research lab that contradicted the scientific belief at the time that RNA was too unstable for clinical use. Dr. Hoerr found that to the contrary, RNA could be administered directly into tissue as a therapeutic vaccine or agent once the biological properties of the molecule were appropriately modified. Based on this novel approach CureVac was born, and continues to grow as a company that develops diverse therapeutic possibilities based on revolutionary vaccination.

CureVac is developing a new class of therapeutics based on mRNA for cancer immunotherapy and prophylactic vaccines for infectious diseases. CureVac’s cancer vaccines are already in Phase IIb, and the prophylactic vaccine approach was published in Nature Biotechnology.

 

Tom Fowler, Medgadget: What was it like for you to transition from being a scientist to running a biotech company?

Ingmar-Hoerr-2Dr. Ingmar Hoerr: When we confirmed that RNA, including antigen-coding messenger RNA, could induce specific cytotoxic T-lymphocytes and antibodies, we realized that we had a significant discovery on our hands. If this vaccination approach could be commercialized and turned into a product, we could potentially change the way patients with debilitating diseases are being treated. I was excited to learn the commercial aspects of taking a novel technology, a completely new approach, out of the lab and transforming it into a therapy for humans.

One of the most important things I learned during my transition from scientist to a CEO is the management of a biotech company from a business perspective. This was just as important as the actual scientific discovery itself. My founding partners and I knew that we needed experienced and motivated individuals to join our team in order to start a successful emerging biotech company. Because of these talented individuals, today CureVac is a group of 120 dedicated employees, and we continue to advance the research and development and commercial potential of RNA-based vaccines.

 

Medgadget: You lived one year in India conducting field studies on leprosy and HIV in collaboration with the World Health Organization. How did this affect your perspective on vaccines?

Dr. Hoerr: India, like many other underdeveloped countries, faces the challenge of a range of horrid infectious diseases such as leprosy. Even if vaccines are available, the delivery of vaccines from manufacturer to recipient can take up to 18 months, and most vaccines require a stable cold chain. This is a major challenge in tropical and developing countries with poor infrastructures.

I experienced first-hand that “classical” vaccines are not suitable to supply such remote and logistically challenging regions, and, if vaccination of people living in these developing countries will ever become a reality, a different approach is necessary. I am very excited that CureVac’s technology may provide people in these challenging and remote regions with cost-effective prophylactic vaccines for different infectious diseases that are stable at elevated as well as freezing temperatures.

 

Medgadget: What are some of the newer targets being researched in your lab for RNA therapeutic vaccines?

Dr. Hoerr: We continue to advance our therapeutic mRNA-based (RNActive®) cancer immunotherapy for prostate cancer and lung cancer for which we are currently in clinical trials, and we are working to identify and develop other cancer immunotherapy candidates. We are also developing prophylactic vaccines and are currently evaluating an RNActive®-based rabies vaccine in a Phase I trial to assess safety and tolerability in healthy volunteers and to determine the dose and evaluate routes of delivery.

In our collaboration with Sanofi Pasteur we are working on other promising targets. Our pre-clinical data have shown that RNActive® vaccines are suitable for viral, bacterial and protozoan infections.

 

Medgadget: CureVac recently won a $2.7 million vaccine prize from the European Commission for developing prophylactic vaccines that can reach remote areas in the world without the need for cooling. Will this shift the company focus toward developing countries and aid work?

Dr. Hoerr: Although we are currently focused on indications that primarily affect the Western world, we do plan to expand to developing countries once we are revenue-generating. This $2.7 million grant will help us in that effort dramatically. Furthermore we signed a framework agreement with the Bill & Melinda Gates Foundation to work in this field.

 

Medgadget: How is CureVac changing the future of healthcare?

Dr. Hoerr: For a long time it was thought that it is impossible to utilize RNA, the oldest biomolecule, for medical purposes. It was generally accepted that, despite their advantages, messenger (m)RNAs were too unstable and too difficult to manipulate to be efficiently used in the medical field. We overcame these hurdles, and today we can modify and improve messenger RNA by sequence-modification, using naturally occurring nucleotides that greatly enhance the stability and the translation levels without changing the amino acid sequence of the corresponding protein. Now we can harness the previously unknown capabilities of this molecule.

Our goal is to provide the patient’s body with the specific information that is stored in the RNA and allow the body produce its own, custom-tailored therapeutics or prophylactic vaccines. Importantly, mRNA is non-replicative and its half-life does not usually exceed a few days, which makes mRNA a transient and safe genetic carrier that has been shown to t stimulate both humoral (antibody-mediated) responses and cellular (antigen-specific T-cell) responses.

mRNA-based therapeutics are a novel therapeutic class with nearly limitless opportunity. They have a broad applicability for the treatment of human disease and have just begun to transform modern molecular medicine.

 

Medgadget: What encouragement do you have for PhD candidates and medical technology entrepreneurs that are early in their careers?

Dr. Hoerr: Follow your instincts and fascinations. Don’t be afraid to think outside the box. Remain curious and don’t be afraid to take risks!

divider

 

Link: CureVac website…

Tom Fowler

Tom Fowler worked as a programmer in the healthcare IT industry before settling back in school to learn how to become a doctor. He likes to dabble with biotech startups, write postcards to his relatives, and play his ukulele. He was a TEDMED '13 scholar, has published research in biomedical informatics, and continues to advocate for international maternal and child health. Currently in the SELECT MD leadership program at USF Health Morsani College of Medicine.

Sponsored
C-mo Medical Solutions extends seed investment round to €4.8 million to transform cough monitoring

C-mo Medical Solutions extends seed investment round to €4.8 million to transform cough monitoring

New Clarius Power Fan HD3 Delivers a First for Handheld Ultrasound: Continuous Scanning

New Clarius Power Fan HD3 Delivers a First for Handheld Ultrasound: Continuous Scanning

Fluidx Unveils New Embolic for Neurovascular Use

Fluidx Unveils New Embolic for Neurovascular Use

Annalise.ai and Nuance Communications (a Microsoft Company) Announce Key Partnership to Improve Patient Outcomes with Workflow-Integrated AI

Annalise.ai and Nuance Communications (a Microsoft Company) Announce Key Partnership to Improve Patient Outcomes with Workflow-Integrated AI

PT Genie Unveils New Brand Identity Reflecting Company’s Transformation and Focus on the Global Future of AI and Machine Learning in Digital Healthcare

interviews & reviews
Balance Boards to Stay Active in the Offfice: Interview with Joel Heath, CEO of FluidStance 

Balance Boards to Stay Active in the Offfice: Interview with Joel Heath, CEO of FluidStance 

Exciting Medtech at the Healthcareᐩ Expo Taiwan

Exciting Medtech at the Healthcareᐩ Expo Taiwan

Medgadget Visits Healthcareᐩ Expo Taiwan

Medgadget Visits Healthcareᐩ Expo Taiwan

Diabetes Management Tech for Type II patients: Interview with Jeffrey Brewer, CEO of Bigfoot Biomedical

Diabetes Management Tech for Type II patients: Interview with Jeffrey Brewer, CEO of Bigfoot Biomedical

Monitoring Congestive Heart Failure Through Speech: Interview with Tamir Tal, CEO of Cordio Medical

Monitoring Congestive Heart Failure Through Speech: Interview with Tamir Tal, CEO of Cordio Medical

In-Office Pediatric Ear Tube Procedures: Interview with Preceptis Medical's Greg Mielke

In-Office Pediatric Ear Tube Procedures: Interview with Preceptis Medical's Greg Mielke

Symani Microsurgical Robotic System: Interview with Mark Toland, CEO of Medical Microinstruments

Symani Microsurgical Robotic System: Interview with Mark Toland, CEO of Medical Microinstruments

  • Subscribe
  • Contact us
  • Submit
  • About
  • Back to top
Medgadget

Medical technologies transform the world! Join us and see the progress in real time. At Medgadget, we report the latest technology news, interview leaders in the field, and file dispatches from medical events around the world since 2004.

  • About
  • Editorial policies
  • Contact
  • Terms of Service
  • Privacy
  • Submit press release
  • Advertise
© Medgadget, Inc. All rights reserved. | The Medical Revolution Will Be Blogged.
Please support this website by adding us to your whitelist in your ad blocker. Ads are what helps us bring you premium content! Thank you!
Posting....
  • Facebook
  • Twitter
  • LinkedIn
  • Reddit
  • Email